Xanomeline-Trospium: A Muscarinic Alternative to Dopamine Blockade

This narrative review consolidates the pharmacology, pharmacokinetics, and EMERGENT trial data behind the first non-dopaminergic antipsychotic, giving psychopharmacology pharmacists a mechanistic and practical framework for counseling and monitoring.

xanomelinetrospium chlorideCobenfyKarXTmuscarinic agonistM1 M4 receptorschizophreniaantipsychoticEMERGENT trialsPANSSnarrative reviewpsychopharmacology Psychiatry / Psychopharmacology

Background Information

Cobenfy offers a novel way to treat schizophrenia with fewer side effects.

Cobenfy, combining xanomeline and trospium, offers a novel schizophrenia treatment minimizing common antipsychotic side effects. Cobenfy reduced PANSS scores significantly with a least squares mean difference of -9.6 and -8.4 in two trials. Major side effects include nausea and constipation. This new mechanism provides a valuable alternative for schizophrenia patients, especially those intolerant to dopamine antagonists. Long-term safety data are yet needed. Cobenfy effectively treats schizophrenia with fewer metabolic and extrapyramidal side effects than traditional antipsychotics.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Avila S, Chen IL

Citation: Avila S, Chen IL Xanomeline and Trospium Chloride: Mechanism of Action, Clinical, and Translational Science. Clinical and translational science. 2026;19(9):e70725. doi:10.1111/cts.70725

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →